{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T23:14:32Z","timestamp":1781738072047,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","award":["Bayer"],"award-info":[{"award-number":["Bayer"]}],"id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The NFLymSI-18 is a patient-reported outcome measure comprised of the highest priority symptoms, emotional concerns, treatment side effects, and other concerns identified by lymphoma patients and oncologists. This study assessed the content validity of the NFLymSI-18 for patients with indolent B-cell non-Hodgkin\u2019s lymphoma (iNHL), with a focus on the Disease-Related Symptoms Physical (DRS-P) subscale.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with a confirmed iNHL diagnosis who had received one or more lines of treatment were recruited during clinic visits. Patients described their symptoms, treatment side effects, and emotional concerns related to iNHL in a semi-structured interview. Qualitative data were analyzed using NVivo10.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Data saturation was obtained by the 18th interview. Most participants (67%) had follicular lymphoma. 28% of participants had marginal zone lymphoma, and one participant had lymphoplasmacytoid lymphoma\/Waldenstr\u00f6m macroglobulinemia. Mean age of the 18 participants was 67 years. 56% of the sample was male. Most participants (67%) had a college or advanced degree. When asked to describe their iNHL symptoms, patients most often discussed swelling (<jats:italic>n<\/jats:italic>\u2009=\u200914), fatigue (<jats:italic>n<\/jats:italic>\u2009=\u200911), and pain (<jats:italic>n<\/jats:italic>\u2009=\u20098). The following symptoms were mentioned by three patients each: anxiety, appetite loss, rash, sleep disruption, trouble breathing, and malaise. Mapping of NFLymSI-18 content to these concerns showed the instrument includes all those most frequently mentioned symptoms.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study supports the content validity of the NFLymSI-18, including its DRS-P Subscale, for patients with iNHL. The instrument shows strong validity for the most referenced symptoms of swelling, fatigue, and pain. The diversity of additional symptoms reported by patients is consistent with the heterogeneous symptomology of iNHL.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41687-024-00752-6","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T12:06:41Z","timestamp":1720526801000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Content validation of the National Comprehensive Cancer Network\/Functional Assessment of Cancer Therapy Lymphoma Symptom Index-18 (NFLymSI-18) in indolent B-cell non-Hodgkin\u2019s lymphoma"],"prefix":"10.1186","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8229-3780","authenticated-orcid":false,"given":"Courtney N.","family":"Hurt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Shaunfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly A.","family":"Webster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Keating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Boyken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Duffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"issue":"4","key":"752_CR1","first-page":"338","volume":"8","author":"A Ciobanu","year":"2013","unstructured":"Ciobanu A, Stanca O, Triantafyllidis I, Lupu A (2013) Indolent lymphoma: diagnosis and prognosis in medical practice. Maedica Sep 8(4):338\u2013342","journal-title":"Maedica Sep"},{"key":"752_CR2","doi-asserted-by":"publisher","unstructured":"Shankland KR, Armitage JO, Hancock BW (2012) Non-Hodgkin lymphoma. Lancet (London, England) 380(9844):848\u2013\u200957. https:\/\/doi.org\/10.1016\/s0140-6736(12)60605-9","DOI":"10.1016\/s0140-6736(12)60605-9"},{"key":"752_CR3","unstructured":"Leukemia & Lymphoma Society. Treatment for indolent NHL subtypes. https:\/\/www.lls.org\/lymphoma\/non-hodgkin-lymphoma\/nhl-subtypes\/treatment-indolent-nhl-subtypes. Accessed 14 June 2023"},{"issue":"1","key":"752_CR4","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1148\/rg.301095088","volume":"30","author":"FM Paes","year":"2010","unstructured":"Paes FM, Kalkanis DG, Sideras PA, Serafini AN (2010) FDG PET\/CT of extranodal involvement in non-hodgkin lymphoma and Hodgkin disease. Radiographics 30(1):269\u2013291. https:\/\/doi.org\/10.1148\/rg.301095088","journal-title":"Radiographics: Rev Publication Radiological Soc North Am Inc Jan"},{"issue":"1","key":"752_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/annonc\/mdh002","volume":"15","author":"SA Pileri","year":"2004","unstructured":"Pileri SA, Zinzani PL, Went P, Pileri A Jr., Bendandi M (2004) Indolent lymphoma: the pathologist\u2019s viewpoint. Ann Oncol 15(1):12\u201318","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol \/ ESMO Jan"},{"issue":"4","key":"752_CR6","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/ajh.23674","volume":"89","author":"A Freedman","year":"2014","unstructured":"Freedman A (2014) Follicular lymphoma: 2014 update on diagnosis and management. Am J Hematol 89(4):429\u2013436. https:\/\/doi.org\/10.1002\/ajh.23674","journal-title":"Am J Hematol Apr"},{"issue":"4","key":"752_CR7","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/j.1365-2141.2011.08969.x","volume":"156","author":"C McNamara","year":"2012","unstructured":"McNamara C, Davies J, Dyer M et al (2012) Guidelines on the investigation and management of follicular lymphoma. Br J Haematol 156(4):446\u2013467. https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08969.x","journal-title":"Br J Haematol Feb"},{"issue":"2","key":"752_CR8","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s12185-010-0674-x","volume":"92","author":"P Solal-Celigny","year":"2010","unstructured":"Solal-Celigny P, Cahu X, Cartron G (2010) Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful? Int J Hematol 92(2):246\u2013254. https:\/\/doi.org\/10.1007\/s12185-010-0674-x","journal-title":"Int J Hematol Sep"},{"key":"752_CR9","unstructured":"National Cancer Institute. Adult Non-Hodgkin lymphoma treatment (PDQ\u00ae)\u2013Health Professional Version. National Cancer Institute. http:\/\/www.cancer.gov\/types\/lymphoma\/hp\/adult-nhl-treatment-pdq. Accessed 29 June 2016"},{"key":"752_CR10","unstructured":"Webster K, Cella D (1998) Quality of life in patients with low-grade non-Hodgkin\u2019s lymphoma. Oncology (Williston Park, NY). 12(5):697\u2013714; discussion 714, 717, 721"},{"issue":"3","key":"752_CR11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1177\/2040620711407675","volume":"2","author":"MS Walker","year":"2011","unstructured":"Walker MS, Stepanski EJ, Reyes C, Satram-Hoang S, Houts AC, Schwartzberg LS (2011) Symptom burden and quality of life in patients with follicular lymphoma undergoing maintenance treatment with Rituximab compared with Observation. Therapeutic Adv Hematol Jun 2(3):129\u2013139. https:\/\/doi.org\/10.1177\/2040620711407675","journal-title":"Therapeutic Adv Hematol Jun"},{"key":"752_CR12","unstructured":"MD Anderson Cancer Center. Non-Hodgkin\u2019s lymphoma symptoms, University of Texas MD Anderson Cancer Center. http:\/\/www.mdanderson.org\/patient-and-cancer-information\/cancer-information\/cancer-types\/non-hodgkins-lymphoma\/symptoms\/index.html. Accessed 29 June 2016"},{"key":"752_CR13","unstructured":"Leukemia & Lymphoma Society. Non-Hodgkin lymphoma signs and symptoms. Leukemia & Lymphoma Society. https:\/\/www.lls.org\/lymphoma\/non-hodgkin-lymphoma\/signs-and-symptoms. 29 Accessed June 2016"},{"key":"752_CR14","unstructured":"American Cancer Society. Signs and symptoms of non-Hodgkin lymphoma. American Cancer Society. http:\/\/www.cancer.org\/cancer\/non-hodgkinlymphoma\/detailedguide\/non-hodgkin-lymphoma-signs-symptoms. Accessed 27 July 2016"},{"key":"752_CR15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1477-7525-4-79","volume":"4","author":"Guidance for industry","year":"2006","unstructured":"U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Devices and Radiological (2006) Health guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 4:79. https:\/\/doi.org\/10.1186\/1477-7525-4-79","journal-title":"Health Qual Life Outcomes"},{"key":"752_CR16","doi-asserted-by":"crossref","unstructured":"Rosenbloom S, Yount S, Yost K et al (2008) Development and validation of eleven symptom indices to evaluate response to chemotherapy for advanced cancer: measurement compliance with regulatory demands. In: Farquhar ISK, Sorkin A (eds) The value of innovation: impacts on health, life quality, and regulatory research. Emerald Group Publishing Inc, pp 53\u201366","DOI":"10.1016\/S0194-3960(08)16003-6"},{"issue":"3","key":"752_CR17","doi-asserted-by":"publisher","first-page":"268","DOI":"10.6004\/jnccn.2011.0026","volume":"9","author":"D Cella","year":"2011","unstructured":"Cella D, Rosenbloom SK, Beaumont JL et al (2011) Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer. J Natl Compr Cancer Netw 9(3):268\u2013278. https:\/\/doi.org\/10.6004\/jnccn.2011.0026","journal-title":"J Natl Compr Cancer Network: JNCCN Mar"},{"key":"752_CR18","unstructured":"Cella D (1997) FACIT manual: Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) measurement system. Center on Outcomes, Research and Education"},{"issue":"3","key":"752_CR19","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","volume":"11","author":"DF Cella","year":"1993","unstructured":"Cella DF, Tulsky DS, Gray G et al (1993) The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11(3):570\u2013579","journal-title":"J Clin Oncol Mar"},{"key":"752_CR20","unstructured":"Webster K, Odom L, Peterman A, Lent L, Cella D (1999) The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: validation of version 4 of the core questionnaire. Qual Life Res 604\u2013604"},{"issue":"9","key":"752_CR21","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.3109\/10428194.2012.762977","volume":"54","author":"FJ Hlubocky","year":"2013","unstructured":"Hlubocky FJ, Webster K, Beaumont J et al (2013) A preliminary study of a health related quality of life assessment of priority symptoms in advanced lymphoma: the National Comprehensive Cancer Network-Functional Assessment of Cancer therapy\u2013 lymphoma Symptom Index. Leuk Lymphoma 54(9):1942\u20131946. https:\/\/doi.org\/10.3109\/10428194.2012.762977","journal-title":"Leuk Lymphoma"},{"key":"752_CR22","unstructured":"Bayer A (2023) Phase III, Randomized, double-blind, controlled multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed Indolent non-Hodgkin\u2019s Lymphoma (iNHL). https:\/\/clinicaltrials.gov\/"},{"issue":"5","key":"752_CR23","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/s1470-2045(21)00145-5","volume":"22","author":"MJ Matasar","year":"2021","unstructured":"Matasar MJ, Capra M, \u00d6zcan M et al (2021) Copanlisib plus Rituximab versus placebo plus rituximab in patients with relapsed indolent non-hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 22(5):678\u2013689. https:\/\/doi.org\/10.1016\/s1470-2045(21)00145-5","journal-title":"Lancet Oncol May"},{"issue":"4","key":"752_CR24","doi-asserted-by":"publisher","first-page":"e401","DOI":"10.1002\/hsr2.401","volume":"4","author":"S Shaunfield","year":"2021","unstructured":"Shaunfield S, Yount SE, Boyken L, Agulnik M, Samant S, Cella D (2021) Optimizing brief, focused assessment of priority symptoms and concerns in recurrent and\/or metastatic squamous cell carcinoma of the head and neck: content validation of the Functional Assessment of Cancer Therapy\/National Comprehensive Cancer Network Head and Neck Symptom Index-10 (FHNSI-10). Health Sci Rep 4(4):e401. https:\/\/doi.org\/10.1002\/hsr2.401","journal-title":"Health Sci Rep"},{"issue":"3","key":"752_CR25","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.cllc.2012.07.001","volume":"14","author":"S Magasi","year":"2013","unstructured":"Magasi S, Mallick R, Kaiser K et al (2013) Importance and relevance of pulmonary symptoms among patients receiving second- and third-line treatment for advanced non\u2013small-cell lung cancer: support for the content validity of the 4-Item Pulmonary Symptom Index. Clin Lung Cancer 14(3):245\u2013253. https:\/\/doi.org\/10.1016\/j.cllc.2012.07.001","journal-title":"Clin Lung Cancer"},{"issue":"6","key":"752_CR26","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1111\/j.1524-4733.2009.00547.x","volume":"12","author":"DE Victorson","year":"2009","unstructured":"Victorson DE, Anton S, Hamilton A, Yount S, Cella D (2009) A conceptual model of the experience of dyspnea and functional limitations in chronic obstructive pulmonary disease. Value Health 12(6):1018\u20131025","journal-title":"Value Health: J Int Soc Pharmacoeconomics Outcomes Res"},{"issue":"5","key":"752_CR27","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/j.1524-4733.2010.00702.x","volume":"13","author":"DT Eton","year":"2010","unstructured":"Eton DT, Shevrin DH, Beaumont J, Victorson D, Cella D (2010) Constructing a conceptual framework of patient-reported outcomes for metastatic hormone-refractory prostate cancer. Value Health 13(5):613\u2013623. https:\/\/doi.org\/10.1111\/j.1524-4733.2010.00702.x","journal-title":"Value Health Aug"},{"key":"752_CR28","doi-asserted-by":"crossref","unstructured":"Willis GB (2005) Cognitive interviewing: a tool for improving questionnaire design. Sage","DOI":"10.4135\/9781412983655"},{"issue":"1","key":"752_CR29","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1177\/1468794107085301","volume":"8","author":"GA Bowen","year":"2008","unstructured":"Bowen GA (2008) Naturalistic inquiry and the saturation concept: a research note. Qual Res 8(1):137\u2013152","journal-title":"Qualitative Research:QR"},{"issue":"1","key":"752_CR30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1525822X05279903","volume":"18","author":"G Guest","year":"2006","unstructured":"Guest G, Bunce A, Johnson L (2006) How many interviews are enough? An experiment with data saturation and variability. Field Meth 18(1):59\u201382","journal-title":"Field Meth"},{"issue":"3","key":"752_CR31","doi-asserted-by":"publisher","first-page":"A33","DOI":"10.1016\/j.jval.2015.03.198","volume":"18","author":"RE Lamoureux","year":"2015","unstructured":"Lamoureux RE, Shields A, Stokes J, Yaworsky A, Galipeau N (2015) How many subjects are enough for symptom-focused concept elicitation studies? A retrospective analysis of saturation across twenty-six studies. Value Health 18(3):A33. https:\/\/doi.org\/10.1016\/j.jval.2015.03.198","journal-title":"Value Health"},{"key":"752_CR32","doi-asserted-by":"crossref","unstructured":"Glaser BGSA (1967) The discovery of grounded theory: strategies for qualitative research. Aldine","DOI":"10.1097\/00006199-196807000-00014"},{"issue":"8","key":"752_CR33","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1111\/j.1524-4733.2009.00603.x","volume":"12","author":"M Rothman","year":"2009","unstructured":"Rothman M, Burke L, Erickson P, Leidy NK, Patrick DL, Petrie CD (2009) Use of existing patient-reported outcome (PRO) instruments and their modification: the ISPOR Good Research practices for evaluating and documenting content validity for the use of existing instruments and their modification PRO Task Force Report. Value Health 12(8):1075\u20131083. https:\/\/doi.org\/10.1111\/j.1524-4733.2009.00603.x","journal-title":"Value Health"},{"issue":"5","key":"752_CR34","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"3","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 3(5):365\u2013376","journal-title":"J Natl Cancer Inst Mar"},{"key":"752_CR35","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jare.2021.06.006","volume":"35","author":"XQ Zheng","year":"2022","unstructured":"Zheng XQ, Wu YH, Huang JF, Wu AM (2022) Neurophysiological mechanisms of cancer-induced bone pain. J Adv Res 35:117\u2013127. https:\/\/doi.org\/10.1016\/j.jare.2021.06.006","journal-title":"J Adv Res Jan"},{"key":"752_CR36","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ejca.2016.10.021","volume":"71","author":"R von Moos","year":"2017","unstructured":"von Moos R, Costa L, Ripamonti CI, Niepel D, Santini D (2017) Improving quality of life in patients with advanced cancer: targeting metastatic bone pain. Eur J Cancer 71:80\u201394. https:\/\/doi.org\/10.1016\/j.ejca.2016.10.021","journal-title":"Eur J Cancer Jan"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-024-00752-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-024-00752-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-024-00752-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T12:14:46Z","timestamp":1720527286000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-024-00752-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["752"],"URL":"https:\/\/doi.org\/10.1186\/s41687-024-00752-6","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,9]]},"assertion":[{"value":"8 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures were approved by the Northwestern University Institutional Review Board and all participants provided informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"K. Kaiser, SS, KW, JG, and DC have faculty appointments at Northwestern University Feinberg School of Medicine, which received funding from Bayer Healthcare Pharmaceuticals for the conduct of this study, although not for manuscript development. K. Keating is an employee at Bayer HealthCare Pharmaceuticals, which funded this study. DC and KW are officers of FACIT.org. LB, SD, and CH have no competing interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"68"}}